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ABSTRACT 
Objective: Coconut oil (CO) was used in combination with metronidazole in order to prepare vaginal pessaries ameliorating the use, delivery and 
efficacy of the anti-mycotic treatment.  
Methods: To prepare the metronidazole–loaded pessaries, different lipids, namely: suppocire NA15 (SNA), suppocire NAIS10 (SIS), suppocire AM 
(SAM) and ovucire WL 2944 (OWL) were used alone or in combination with coconut oil in a ratio of 1:1. Prepared pessaries were subjected to 
characterization and evaluation of physical properties, drug release, anti-microbial effect, in vivo studies and histopathological examination. 
Results: In the case of all the lipids, coconut oil improved the physical properties which can allow better use and performance of the pessaries. 
Among the prepared pessaries, the OWL/CO-based pessary (P8) showed the highest drug release profile (P<0.05). Characterization was done using 
X-Ray diffraction. Microbiological study showed the superiority of OWL/CO-based pessaries over OWL-based pessaries at different time intervals. 
Histopathological studies of the vagina of female Wistar rats showed that in the case of the Candida albicans-infected group treated with the selected 
pessary, the mucosal and muscular layer returned to its normal structure, in addition to the disappearance of the cauliflower-like projections and 
the newly formed blood capillaries, seen in the Candida albicans-infected group. The questionnaire done in volunteers suffering from recurrent 
vaginal infection reported a significant decrease (reaching 93 %) in the severity of the symptoms, after the use of the suggested pessaries (P8) 
(P<0.05). Also, the suggested product had high patient acceptability. The results reported after the use of P8 were better than those of Amrizole® 
vaginal suppository.  
Conclusion: The current study can present a successful, effective and easy to use product with low cost and minimal side effects.  
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A large number of women suffer from recurrent vulvovaginal 
candidiasis. The manifestations of vulvovaginal candidiasis are often 
painful and uncomfortable and can include intense itching, irritation, 
vaginal discharge and dysuria [1], in addition to some issues related to 
social burden. Infectious vaginitis appears as a result of a violation of 
the normal flora of the vagina, which suppresses the immune response 
of the host and pathogenic microorganisms entering the vagina [2]. 
Although there is an expansion in the development of vaginal 
healthcare product, many of them didn’t attain the desired patient 
acceptability as well as required biological safety and effectiveness. 
Most of the recorded problems are related to discontinuing use due 
to the low patient acceptability, which in turn increases the 
recurrences [3]. Therefore, there is a continuous need for safe, 
efficacious and well-tolerated regimens that reduce the incidence of 
vaginal infections over prolonged periods. 
Oral and intravaginal metronidazole (MTZ) are used, in an average 
dose of 500 mg daily, for the treatment of vaginal candidiasis [4]. Many 
reports focus on the utility of vaginal delivery of antimicrobial drugs 
compared to oral therapy due to several advantages including higher 
localized drug concentration and lower systemic exposure [3, 5-7]. 
This may be especially important in the case of pregnant patients. 
Vaginitis seems to be a complex infection, and very often, it is not 
possible to identify only one causative agent due to a mixed infection. 
In such cases, a multi-functional treatment seems to be crucial [2].  
Ethnomedicine is concerned with the use of natural oils in medicine 
due to their multiple biological functions comprising: anti-
inflammatory, anti-oxidant, anti-microbial, cytoprotective and anti-
aging properties [8-10], in addition to its great economic interest and 
multiple nutritional and pharmaceutical values together with their 
safety. Coconut oil (CO) is obtained from Cocos nucifera Linn (Palmae) 
[11] and is present in the form of a white paste below 25 ⁰C; this can 
provide an advantage for the preparation of vaginal pessaries. Early 
studies suggest that medium-chain fatty acids (MCFA), commonly 
found in tropical oils such as coconut oil (CO), are bactericidal for 
gram-positive and gram-negative bacteria, fungi, protozoa, and viruses 
[12, 13]. Some studies have reported the efficacy of CO against Candida 
albicans [14, 15]. CO consists of 99% triglycerides with free fatty acids 
(less than 0.2%) [16], in addition to lauric acid (C12), caprylic (C8) and 
capric acids (C10) [16], these components have been reported to 
exhibit an antimicrobial activity [17]. A proposed mechanism for the 
effects of CO suggests that membrane lipids are solubilized as the CO 
fatty acids integrate into the membrane. Electron microscopy 
demonstrates the disruption of bacterial cell membrane when exposed 
to CO fatty acids with subsequent lysis of the bacteria [12]. 
According to Gatefossé, suppocire® and ovucire® products are hard 
fat semi-synthetic bases produced by esterification of fatty acids. 
Their composition consists of a mixture of C12–C18 triglycerides. 
They can be used for vaginal and rectal delivery and have many 
advantages being inert, compatible with a wide variety of active 
ingredients, chemically stable, tolerance to the mucosa, safe and 
non-irritant (www. gatefosse. com).  
Vaginal health care products must be sufficiently acceptable, 
accessible and easy to use so that they are used correctly and 
consistently; this is necessary to eradicate the vaginal infection. In 
2004, the International Working Group for Microbicides (IWGM) 
published a list of “essential characteristics for a topical 
microbicide”[18], these are: effective, safe and easy to use.  
This study aimed to improve the use, delivery and effect of 
metronidazole (MTZ) for the treatment of recurrent vaginal 
infections. Different lipids were used to prepare MTZ pessaries, 
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namely, suppocire NA (SNA), suppocire NAIS (SIS), suppocire AM 
(SAM) and ovucire WL (OWL). These lipids were used alone or in 
conjunction with coconut oil (CO), which is a natural component 
with many beneficial effects and low side effects, in addition to its 
availability and low cost. The prepared pessaries were compared 
based on different physicochemical properties; then the selected 
pessaries were subjected to microbiological studies in experimental 
animals followed by histopathological examination and preliminary 
clinical investigation.  
MATERIALS AND METHODS 
Materials 
Metronidazole was purchased from El-Nasr chemical company, 
Egypt. Suppocire NA15 (SNA), suppocire NAIS10 (SIS), suppocire 
AM (SAM) and ovucire WL 2944 (OWL) was kindly supplied from 
Gattefosseé établissements, France. Pure edible coconut oil (CO) 
which solidifies below 25 ⁰C, and melts at around 30 ⁰C to form a 
liquid, was purchased from Hemani Int., Karachi, Pakistan. 
Sabouraud dextrose agar was purchased from Oxoid, England; its 
typical composition (g/l) is mycological peptone 10.0; glucose 40.0; 
agar 15.0, pH 5.6±02. Sabouraud liquid medium was purchased from 
Oxoid, England. Candida albicans was isolated from the vaginal swab 
of a patient with vaginal candidiasis who had received no antifungal 
therapy. All other chemicals used in the study were of analytical 
grade and were obtained from the El-Nasr Company for 
Pharmaceutical Chemicals (Cairo, Egypt). 
Formulation of MTZ-loaded pessaries 
Metronidazole (MTZ) pessaries, each containing 500 mg of the drug, 
were formulated using the fusion method. Briefly, the lipid was 
melted first using a water bath then coconut oil was added (in the 
case of the pessaries formed from lipid/coconut oil in a ratio of 1:1 
w/w). MTZ was then added to the melted base under gentle stirring 
to ensure complete mixing and to enhance cooling. The mass was 
poured into a metal mould just before congealing. After solidification 
at room temperature, the prepared pessaries were packed in tightly 
closed containers and placed in a refrigerator. The composition of 
the different formulae is listed in table 1. 
Physical evaluation of MTZ-loaded pessaries 
Weight variation 
The average weight was calculated by weighing 6 pessaries 
individually and the percentage deviation from the mean was 
determined.  
Disintegration time 
The test was performed in buffer pH 4.5 at 37±0.5 °C using Erweka 
tablet disintegration apparatus, Germany [19]. The disintegration 
time was recorded as soon as the pessaries placed in the basket 
either completely melt or dissolve according to the British 
Pharmacopoeia [20].  
Hardness  
This test was designed to measure the brittleness and fragility of the 
pessaries. The resistance of the prepared pessaries was evaluated 
using Erweka hardness tester (Germany) [19] under the effect of 
increasing pressure at room temperature. The force (Kg/cm2) 
required for the deformation and breaking of the pessaries was 
calculated. 
Melting range  
The test was carried out using the capillary method [21] in melting 
point apparatus. A straight capillary tube, 8 to 10 cm in length and 
1 to 1.2 mm in internal diameter, opened at both ends was used. 
One end of the tube was dipped into the suppository bases, and 
gently sufficient amount was packed to fill 1 cm of the column (no 
previous melting of the sample was done to avoid changing any 
stable modification to unstable one). The capillary tube was then 
placed in the apparatus attached to a thermometer. The melting 
range was recorded when the contents of the capillary tube 
started to melt. 
In vitro release  
The in vitro dissolution studies were carried out using a USP rotating 
basket apparatus (Hanson Research Corporation, United States). The 
pessaries were placed in the baskets which were rotated at 50 rpm in 
500 ml phosphate buffer pH 4.5 maintained at 37±0.5 °C [3]. An aliquot 
of 5 ml of the solution was withdrawn at predetermined time intervals 
and replaced by fresh dissolution medium. The withdrawn samples were 
analyzed for MTZ content spectrophotometrically at a λmax of 318 nm. 
Blank experiments were run in parallel to avoid any interaction. 
Some release parameters were calculated to compare between 
investigated formulae [22], these comprised:  
Release efficiency (RE) which is defined as the area under the release 
curve (AUC) at time t, calculated using the trapezoidal rule.  
Mean release time (MRT) which is a measure of the release or dissolution 
rate; the higher the MRT, the slower is the release rate [23, 6]. 
Both, the MRT and RE, are model independent approaches which 
allow evaluating the drug release [24].  
Also, kinetics of drug release was determined by finding the best fit 
of the release data to distinct models: zero-order and Higuchi order. 
X-ray diffraction 
The X-ray powder diffraction patterns of MTZ, coconut oil, ovucire 
WL 2944 (OWL), and the selected preparation were recorded on a 
Diano X-ray diffractometer (Scintag Inc., USA). Samples were 
irradiated using Ni-filtered, CuKα radiation at a voltage of 45 kV, and 
a 9 mA current. The scanning rate employed was 1 ° min–1 over 0 ° to 
90 ° diffraction angle (2θ) range. 
Assessment of the antimicrobial activity  
The antimicrobial activity was assessed using the inhibition zone 
test [3, 25]. The agar medium was prepared by dissolving 65 g of 
sabouraud dextrose agar powder per liter of distilled water and, 
then autoclaved at 121 °C for 20 min. A turbid 48-h culture of C. 
albicans prepared in 200 ml liquid Sabouraud medium; turbidity 
was adjusted to contain approximately 105cells/ml then poured into 
sterilized Petri plates under laminar air flow, allowed to solidify and 
then 4 uniform grooves were cut into the solidified media in each 
plate using a sterilized test tube. The MTZ-loaded pessaries 
(containing 20 mg drug) [26], P4 and P8, were suspended in 10 ml 
phosphate buffer pH 4.5 and shaken at room temperature at 50 rpm. 
At different time intervals (15, 30, 60 and 120 min), a sample of 2 ml 
was withdrawn and filled into the different done cups using 
sterilized syringes, under laminar air flow. The withdrawn samples 
were replenished with fresh one [3]. Plates were covered with lids 
and incubated at 32 °C for 40 h. The zones of inhibition were 
examined and their diameters were measured after 40 h [27]. 
In vivo studies 
Animals 
Female Wistar rats weighing between 180 and 220 g (6–8 w old) were 
obtained from the animal house of the National Research Center, Cairo, 
Egypt. The animals were housed in plastic cages and kept in a 
conditioned atmosphere at 22±3 °C and humidity 50–55 % with 12 h 
light/dark cycles, they were fed standard pellet chow and were 
allowed free access to water. This study was conducted in accordance 
with the European Community guidelines and, was approved by 
animal care and use ethics committee of the faculty of Pharmacy 
Damanhour University (Ethical approval number118 PT4). 
Experiment 
In order to evaluate the antimicrobial activity, vaginal infection was 
induced using the rat vaginal model [28]. Animals were divided into 
four groups each containing 6 rats. At day 0, the rats of the negative 
control group were injected 0.1 ml normal saline intravaginally; 
while, all the other animals were inoculated intravaginally with 107 
yeast cells of C. albicans strain tested in 0.1 ml of saline. The infected 
animals were divided into 2 groups, one group served as a positive 
control which didn't receive any treatment; and the other group was 
treated intravaginally with the selected pessaries (P8) loaded with 
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20 mg of the drug [26], once daily for 6 consecutive days starting 
from the day following the induction of C. albicans infection (day 1, 
2, 3, 4, 5 and 6). At day 7, the animals were sacrificed, and the vagina 
was excised and subjected to histopathological study. 
Histopathological examination 
Autopsy samples were taken from the vagina of different groups of 
female Wistar rats (negative control, positive control and P8) and 
were fixed with formalin for 24 h. Washing was done in tap water 
then; serial dilutions of alcohol (methyl, ethyl and absolute ethyl) were 
used for dehydration. Specimens were cleared in xylene and 
embedded in paraffin at 56 ⁰C in a hot air oven for 24 h. Paraffin bees 
wax tissue blocks were prepared for sectioning at a thickness of 4 μm 
by sledge microtome. The obtained tissue sections were collected on 
glass slides, deparaffinized, and then stained by hematoxylin and eosin 
stain for examination using the electric light microscope. 
Preliminary prospective clinical investigation 
This investigation is an outpatient trial obeying to the 
recommendations of the declaration of Helsinki and approved by the 
ethical committee of the faculty of Pharmacy Damanhour University 
(Approval Number 118 PT4). The questionnaire included healthy, 
normally menstruating women, suffering from recurrent vaginal 
infection and aged 25–50 y. The subjects provided their informed 
consent and were made clearly aware of their right to withdraw from 
the study at any time without giving any reason. The patients were 
instructed to insert the selected, designed pessaries (P8) or the market 
product (Amrizole® vaginal suppository), each containing 500 mg 
MTZ, intravaginally at bedtime for 6 consecutive days, and then to 
respond to the questionnaire involving the symptoms they were 
suffering from [29]: itching, burning, vulvovaginal erythema and 
oedema, and vaginal secretion. The symptom severity was scored 0–3, 
where 0 = absent, 1 = mild, 2 = intense, 3 = very intense. At the end of 
the treatment, treatment efficacy was assessed and categorized as 0 = 
no efficacy; 1 = moderate efficacy; 2 = good efficacy. In addition, a 
questionnaire related to the likeability of the inserted pessaries was 
included in the study, the score was 0-2 starting from 0: not liked, 1: 
moderately liked, 2: highly liked, the parameters included were the 
odor, ease of use, and non-irritancy. 
Statistical analysis 
Data were expressed as the mean±the standard deviation and were 
analyzed using one-way analysis of variance, followed by the least 
significant difference procedure using SPSS 10.0 software. Statistical 
differences are yielding p<0.05 were considered significant. 
RESULTS AND DISCUSSION 
Physical evaluation of the MTZ-loaded pessaries 
Weight variation 
Table 1 is listing the weight of the prepared pessaries, all of them 
showed uniform weight and low weight variation. 
Melting point 
As seen in table 1, the melting points of the lipid/CO-based pessaries 
were lower than the corresponding lipid-based ones; this is due to 
the addition of CO which has a melting point lower than that of the 
lipids under investigation. This can provide more privilege by 
allowing a better dispersion and spreading of the pessary in the 
vaginal lumen to cover the vaginal wall and permit a better contact 
with it, hence, better absorption and effect. A previous study 
reported that in the case of suppositories with lipid bases, lower 
melting point bases had demonstrated better drug release [30]. Also, 
rapid melting of the pessary upon application can decrease the risk 
of its expulsion out of the vaginal lumen.  
Hardness 
The values of the hardness of the prepared pessaries are listed in 
table 1. All of them are in the range of 2.30 to 3.00 Kg/cm2, which is 
an indication of the ability of differently formulated pessaries to 
withstand pressure during handling, shipping and insertion.  
Disintegration time 
The disintegration time of the prepared pessaries are listed in table 
1. All of them were in the range of 4.10-7.00 min with P1 and P8 
attaining the highest and lowest values, respectively. The listed 
values run in parallel with those of the melting point because a 
higher melting point of a lipid base results in higher disintegration 
time. All the lipid/CO-based pessaries had longer disintegration time 
than the corresponding lipid-based one. A rapid disintegration can 
be beneficial as it leads to a rapid spreadability of the pessary in the 
vagina after application, which results in a rapid drug release and 
effect. This also can decrease the possibility of the discharge of the 
pessaries out of the vagina after application.  
From the results displayed above, lipid/CO-based pessaries were 
selected for further investigations rather than a lipid-based 
suppository. The better physical properties of the former can allow 
better use and drug delivery into the vagina, in addition to the 
intrinsic anti-microbial properties of CO; all these factors can permit 
for a better effect and higher patient compliance. 
  
Table 1: Composition and physical properties of the MTZ-loaded pessaries 
Pessary Composition Melting range Melting range (⁰C) Hardness(kg/cm2) Disintegration time (min) 
P1 SIS 2.10±0.20 38-40 3.00±0.19 7.00±0.25 
P2 SAM 2.20±0.10 35-37 2.90±0.17 6.50±0.35 
P3 SNA 2.01±0.30 35-37 2.90±0.15 6.30±0.40 
P4 OWL 2.10±0.10 34-35 2.50±0.10 5.30±0.35 
P5 SIS/CO (1:1) 2.05±0.11 36-37 2.82±0.02 5.00±0.25 
P6 SAM/CO (1:1) 2.21±0.17 34-36 2.60±0.03 4.45±0.25 
P7 SNA/CO (1:1) 2.02±0.20 34-35 2.55±0.01 4.30±0.30 
P8 OWL/CO (1:1) 2.05±0.24 33-34 2.30±0.02 4.10±0.15 
Lipids used were: suppocire NA (SNA), suppocire NAIS (SIS), suppocire AM (SAM) and ovucire WL 2944 (OWL), coconut oil (CO), metronidazole 
(MTZ), The values represent the mean±SD (n = 6) 
 
Table 2: Release parameters: release efficiency (RE), mean release time (MRT) and release kinetics 
Pessaries MRT (min) Release (R2) RE 
Zero-order Higuchi order 
P1 68.67±2.41 0.98 0.95 21.81±2.62 
P2 70.54±5.12 0.99 0.98 28.43±2.66 
P3 67.50±4.29 0.99 0.97 29.31±2.11 
P4 50.22±3.90 0.99 0.99 53.51±4.80 
P5 63.29±5.82 0.97 0.91 26.94±2.36 
P6 58.13±5.12 0.99 0.98 37.13±3.99 
P7 66.73±5.96 0.98 0.92 34.63±3.51 
P8 37.97±4.12 0.92 0.96 65.62±5.62 
The values represent the mean±SD (n = 3) 
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In vitro release studies 
Release profiles are displayed in fig. 1 and release parameters (MRT 
and RE) are listed in table 2. Based on the presented data, it is clear 
that the lipid/CO-based pessaries attained a significantly higher and 
faster drug release than the corresponding lipid-based pessaries (P1 
vs P5, P2 vs P6, P3 vs P7 and P4 vs P8). In the case of CO/lipid 
combination, a less ordered lipid matrix can be obtained by mixing 
lipid-oil ingredients [9], the drug molecules can be arranged in 
between the fatty acid chains or within the lipid layers, and also, in 
the imperfections of the lipid matrix, this can allow a better drug 
escape out of the lipid matrix forming the pessaries, upon contact 
with the external release media. Also, it is clear that P8 (OWL/CO-
based pessaries) attained the highest drug release compared with 
the other lipid/CO-based pessaries. This may be due to the 
differences in the structure of the different lipids which certainly 
affect drug release. A previous study has reported that the difference 
in the chain length and complexity, molecular arrangement and 
viscosity of the lipids led to a difference in the physicochemical 
properties [31]. The drug release profiles were expected from the 
results of the melting point and disintegration time of the prepared 
bases, a lower melting point, and more rapid disintegration allow for 
a faster drug release. Therefore, P8 was selected for the following 
investigations. 
Regarding the best fitting kinetic model (table 2), all the prepared 
pessaries were found to follow a zero-order kinetic model, except 
for P8 which followed a Higuchian model. 
X-rays diffraction 
Fig. 2 is showing the X-rays diffraction pattern of the selected 
formula and each of the components alone. The diffractogram of the 
crystalline drug is showing well-defined, and sharp peaks at 
different positions, the most obvious appear at about 12.15 °, 12.30 
°, and 27.31 °. CO shows a sharp crystalline peak at about 5.40 ° and 
another broad amorphous peak at about 21.08 °.  
OWL shows different sharp peaks at about 4.66 °, 16.65 °, 19.08 ° 
and 21.29 °. While, the diffractogram of the selected pessary (P8) 
doesn't show any clear peak, which can point out to the complete 
fusion and coalition of the ingredients, and the presence of the drug 








































Fig. 1: In vitro release profiles of MTZ from the prepared pessaries, the values represent the mean±SD (n = 3) 
 
 
Fig. 2: X-ray patterns of metronidazole (MTZ), coconut oil (CO), ovucire WL (OWL) and the selected pessary (P8) 
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Assessment of the antimicrobial activity  
To validate the usefulness of the addition of CO to prepare the 
pessaries, the anti-microbial effectiveness of the MTZ-loaded 
OWL/CO-based pessary (P8) was compared with an MTZ-loaded 
OWL-based pessary (P4). Fig. 3 is a bar chart showing the diameter 
of the inhibition zones, at different time intervals, in the case of P4 
and P8. Fig. 4 is presenting the photographs of the agar plates with 
the zones of inhibition of the fungal growth induced by P8 in 
comparison with those induced by P4, at different time intervals. At 
all time intervals, it was clear that the combination between MTZ 
and CO improved the anti-mycotic effect of the MTZ-loaded 
pessaries (p<0.05). This was expected due to the previous reports 
confirming the anti-microbial effect of the oil against Candida 
albicans [14, 15], which can potentiate the effect of MTZ. An 
additional advantage for the CO/lipid combination is the faster drug 
release from the base as discussed above in the in vitro release 
study. In addition, the results displayed above showed that the 
OWL/CO-based pessaries had a lower melting point and faster 
disintegration time than the OWL-based ones; this may allow a 
better dispersion of the pessary in the media and permit a more 
rapid and complete drug release. Another issue is that, upon use, 
lipid/CO base can have a softer texture than that of the lipid alone, 
which can promote its dispersion and spreadability, this can present 
an additional privilege in the case of in vivo use by the formation of a 


























Fig. 3: A bar chart showing the diameter of the inhibition zones at different time intervals in the case of the OWL/CO-based pessary (P8) in 
comparison with the OWL-based pessary (P4), the values represent the mean±SD (n = 4) 
 
  
After 15 min After 30 min 
  
After 60 min After 120 min 
Fig. 4: Zones of inhibition of the fungal growth induced by OWL/CO-based pessary (P8) in comparison with the OWL-based pessary (P4) at 
different time intervals. A: P4, B: P8 
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In vivo study 
Visual examination 
The activity of the selected pessary (P8), in comparison with a 
negative control and a positive control group, was tested in female 
Wistar rats before investigations involving the female volunteer. Fig. 
5 is showing the photographs of the vaginal orifice of the rats at the 
end of the experiment. It is clear that in the case of the positive 
control (C albicans-infected group) the vaginal orifice showed 
erythema, edema and dilatation due to infection and inflammation. 
All these symptoms were absent in the case of the group treated 
with P8, and the vagina looked almost normal and similar to that of 
the negative control. This proves the effectiveness of the designed 
pessary and its capability to combat C. albicans vaginal infection. 
  
 
Fig. 5: Vaginal orifice of female wistar rats, (A) C. albicans-infected rats and treated with the selected preparation (P8), (B) Positive 
control (C. albicans-infected rats and received no treatment), (C) Negative control 
 
Histopathological study 
Fig. 6A is showing the histological pattern of the vagina of the negative 
control group, there was no histopathological alteration, and the 
normal histological structure of the mucosal lining epithelium and the 
underlying muscular layer were recorded. While in fig. 6B, new blood 
capillaries (a)-resulting from the inflammation and edema-can be 
clearly detected. Also, there were mucosal hyperplasia and hyper 
stratification with cauliflower-like projections formation (b) 
associated with inflammatory cells infiltration in the underlying 
muscular layer. In addition, some inflammatory cells infiltration was 
detected in the muscular layer. These histological alterations resulted 
from C. albicans infection in the untreated group. In fig. 6C presenting 
the treated C. albicans-infected group, there was no histopathological 
alteration in the mucosal layer as well as the underlying musculature. 
The mucosal layer returned to its normal structure and the 
cauliflower-like projections disappeared; only a few inflammatory 
cells remained as a result of the defense mechanism. These results 
prove the in vivo efficacy, non-irritancy and mucosal tolerance of the 
suggested OWL/CO-based MTZ pessary. 
  
 
Fig. 6: Histopathological studies, A) Negative control, B) Positive control (C. albicans-infected rats and received no treatment), a) blood 
capillaries, b) cauliflower-like projection, C) Group treated with the selected preparation (C. albicans-infected rats and treated with P8) 
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Preliminary clinical investigation 
After the promising results are shown above about the high 
effectiveness of the suggested vaginal treatment, a preliminary 
questionnaire in women volunteers was run. For a vaginal 
preparation to be effective, it must be used properly and 
consistently. Some vaginal preparations show good results in vitro, 
but fail to do it in vivo due to the lack of acceptability of the 
preparation by the patients; therefore, this questionnaire was done 
to study the possibility of the application of the suggested vaginal 
pessary and to focus on the interplay between the biological and 
physicochemical properties of it. The selected, designed pessaries 






Fig. 7: Results reported by the questionnaire done in a group of women suffering from recurrent vaginal infection after receiving the 
intravaginal treatment, A) Symptoms before and after receiving the treatment, P8 or the market product (Amrizole®). The symptom 
severity was scored 0–3, where 0 = absent, 1 = mild, 2 = intense, 3 = very intense, B) Likeability of the MTZ-loaded pessaries used (P8) 
compared to the market product (Amrizole®), the score was 0-2 starting from 0: not liked, 1: moderately liked, 2: highly liked, the values 
represent the mean±SD (n = 6) 
 
Fig. 7A shows the values of the severity score of the symptoms reported 
due to recurrent vaginal infection like itching, burning, vulvovaginal 
erythema and oedema, and vaginal secretion. The significant difference 
between symptoms severity, before and after treatment with P8 as well 
as Amrizole®, is clear (p<0.05). An improvement was reported in all the 
cases with a % reduction in the severity of the symptoms equal to 80, 
87.64, 93.63, 92.17 and 88.34 in the case of P8, and 74.91, 74.91, 92.17, 
82.33 and 84.79 in the case of Amrizole®, for the itching, burning, 
vulvovaginal erythema and oedema, and vaginal secretion, respectively. 
The designed pessaries showed better results especially regarding the 
itching and burning sensation, this may be due to the intrinsic properties 
of CO, in addition to the rapid disintegration and good dispersion and 
spreadability of P8 in the vaginal lumen allowing it to cover the vaginal 
wall, as explained above. 
Acceptability is a term indicating the willingness to use a certain 
product [29], this factor is crucial for the successfulness of a vaginal 
preparation. The likeability of the preparation was evaluated in 
terms of its ease of use, odor, non-irritancy and efficacy. As shown in 
fig. 7B, for all the cases the designed preparation (P8) was 
moderately to highly liked with an average score of 1.83, 2, 1.67 and 
2 for the efficacy, odor, ease of use and non-irritancy, respectively. 
While, in the case of Amrizole®, the acceptability score was 1.67, 
0.67, 1.50 and 1.17 for the efficacy, odor, ease of use and non-
irritancy, respectively. The higher acceptability of the designed 
pessaries, especially regarding the odor, may be due to the pleasant 
odor of the CO; this can provide an important advantage taking in 
consideration that vaginal infections are frequently accompanied 
with a bad odor which presents an additional disturbing symptom. 
Based on the above listed results, we can point out to that the designed 
OWL/CO-based MTZ pessary obeys to the International Working 
Group for Microbicides (IWGM) guidelines about the necessity for a 
topical microbicide to be effective, safe and easy to use [18]. 
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CONCLUSION 
Balancing what people want (easy to use, pleasant, no side effects, 
low-cost, etc.) with what is feasible (physicochemical and 
formulation issues) will continue to be a challenge facing the 
development of a certain product. This study presents a simple, yet, 
attractive approach to prepare an anti-mycotic treatment to combat 
recurrent vaginal infection using a natural product. This approach 
was based on the use of Coconut oil to potentiate the anti-microbial 
effect of metronidazole and, to ameliorate the physicochemical 
properties of the designed pessaries. The in vitro as well as in vivo 
studies, histopathological examination and preliminary clinical 
investigations highlight the success of the suggested vaginal care 
product. In turn, this can decrease social burden and improve the 
quality of life of a large women population. 
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